
Sign up to save your podcasts
Or


Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.
By STAT4.5
309309 ratings
Adam, Elaine, and Allison discuss the Trump administration’s plan for huge job cuts and a restructuring of the country’s top health care agencies, the approval of the first drug to treat a devastating rare disease, and the bankruptcy of 23andMe. Then, they bring on the chief executive of startup Altis Labs to discuss new data from a study they conducted with AstraZeneca on an AI tool for cancer drug development.

30,678 Listeners

1,896 Listeners

499 Listeners

9,513 Listeners

6,086 Listeners

394 Listeners

61 Listeners

86 Listeners

34 Listeners

505 Listeners

5,473 Listeners

19 Listeners

48 Listeners

387 Listeners

12 Listeners